Pexidartinib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tenosynovial Giant Cell Tumor
Conditions
Tenosynovial Giant Cell Tumor
Trial Timeline
Sep 25, 2020 → Feb 28, 2026
NCT ID
NCT04488822About Pexidartinib
Pexidartinib is a phase 3 stage product being developed by Daiichi Sankyo for Tenosynovial Giant Cell Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT04488822. Target conditions include Tenosynovial Giant Cell Tumor.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04703322 | Phase 2 | Active |
| NCT04526704 | Approved | Completed |
| NCT04488822 | Phase 3 | Active |
| NCT04223635 | Phase 1 | Completed |
| NCT02734433 | Phase 1 | Completed |
Competing Products
2 competing products in Tenosynovial Giant Cell Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 2 | 52 |
| Pexidartinib | Daiichi Sankyo | Approved | 85 |